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COMMENTARY
Under the right conditions: protecting podocytes
from diabetes-induced damage
Imran HA Ali and Derek P Brazil*
See related research by Li et al., http://stemcellres.com/content/4/5/103
Abstract
Hyperglycemia-induced damage to the glomerular
podocyte is thought to be a critical early event in
diabetic nephropathy. Interventions that prevent
podocyte damage or loss have been shown to have
potential for the treatment of diabetic nephropathy. New
data show that conditioned medium from adipocyte-
derived mesenchymal stem cells has the potential to
protect podocytes from high-glucose-induced damage.
Furthermore, epidermal growth factor may be the critical
ingredient mediating this effect. These data suggest that
components of the conditioned medium of
mesenchymal stem cells, in addition to the cells
themselves, may have potential for the treatment of
diseases such as diabetic nephropathy.
A new report from Li and colleagues has identified novel
mechanisms by which glomerular podocytes may be
protected during diabetic nephropathy (DN) [1]. DN is
the leading cause of end-stage renal disease and is defined
by pathological changes in the kidney causing progressive
loss of the glomerular filtration rate, proteinuria and
tubulointerstitial fibrosis [2]. Podocytes are terminally
differentiated epithelial cells that form the filtration barrier
with the glomerular endothelial cells. Under diabetic con-
ditions, high glucose (HG) levels compromise the integrity
of the glomerular filtration barrier via effacement of the
podocyte foot processes and loss of podocytes from the
glomerular basement membrane. This damage to the
filtration barrier triggers a slow inexorable decline in renal
function that can ultimately result in renal failure [3,4].
Currently available treatments can delay, but not prevent,
the development of DN. The need to develop new therap-
ies to target DN is thus essential.
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Mesenchymal stem cells (MSCs) are specialized progeni-
tor cells that possess differentiation, proliferative and
immunomodulatory potential. This, along with their ease of
isolation, makes MSCs potentially an exciting new tool for
regenerative medicine [5]. In this issue of Stem Cell
Research & Therapy, Li and colleagues show that condi-
tioned media of MSCs derived from human adipose tissue
(hAD-MSCs) significantly reduced the apoptosis of HG-
exposed podocytes. The key ingredient in this conditioned
medium is suggested by the authors to be epidermal
growth factor (EGF). Previous data from others suggested a
potential beneficial effect of MSCs in the treatment of acute
renal ischemia and DN [5,6]. hAD-MSCs injected into
diabetic rats caused a reduction in DN severity without
accumulation of MSCs within the kidneys [5]. This group
therefore hypothesized that hAD-MSCs protected the
kidney in a paracrine manner [5]. The potential of condi-
tioned medium from hAD-MSCs to elicit a similar effect
was assessed in the current study.
Li and colleagues used mouse podocyte clone 5 to eluci-
date the mechanism by which MSCs rescue HG-induced
apoptosis of podocytes [1]. To establish a model of HG-
induced podocytic apoptosis in vitro, the authors exposed
the cells to normal glucose, normal glucose + mannitol,
and HG for 24, 48 and 72 hours. An increase in podocyte
apoptosis within the HG group at all time points was
detected compared with the normal glucose and normal
glucose + mannitol groups. This effect correlated with a de-
crease in the expression of podocyte proteins synaptopodin
and nephrin within the HG group at all time points,
suggesting that HG damaged the integrity of the glomerular
filtration barrier.
Having established a model of HG-induced podocyte
apoptosis, Li and colleagues next added MSC conditioned
medium (MSC-CM) or human embryonic lung cell
conditioned media (Wi38-CM) to the podocytes in all
three treatment groups. The addition of MSC-CM
decreased podocyte apoptosis and maintained the levels of
synaptopodin and nephrin expression in the HG group.
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The addition of Wi38-CM had no beneficial effect in this
case. To understand why MSC-CM was more effective
than Wi38-CM, Li and colleagues identified several cyto-
kines that were present at higher levels in the MSC-CM
compared with Wi38-CM. Of these, EGF was secreted in
the greatest quantity. Given the previous reports of EGFs
ability to repair and protect epithelial cells from apoptosis
[7-9], the authors then treated podocytes exposed to HG
with either MSC-CM or recombinant EGF. Flow analysis
AnnexinV/Pi staining and western blot detection of
caspase 3 confirmed the ability of EGF to inhibit HG-
induced podocytic apoptosis. This effect was diminished
when MSC-CM was co-incubated with a neutralizing anti-
body against EGF. This study clearly points to EGF as a
key player within the MSC-CM in inhibiting HG-induced
podocyte damage and apoptosis.
A particularly interesting aspect of this study is the dem-
onstration that EGF plays a critical role in the restoration
of the glomerular filtration barrier. EGF has been previously
shown to promote the survival of epithelial cells of the in-
testine and kidney [7,9]. In contrast to the current study,
others have shown a pathogenic role for the EGF receptor
in DN [10] and progressive glomerulonephritis [11]. The
current study clearly shows a cytoprotective role of EGF on
podocytes exposed to HG. Further study is required to fully
elucidate the disparity around the role of EGF in kidney
disease, and also to more fully define the protective
mechanism triggered by the conditioned medium from
hAd-MSCs for podocytes during DN.
The work here augments seminal work done by others
and identifies a tantalizing new possibility whereby injecting
MSCs themselves for the treatment of DN (and indeed
other diseases) may not be necessary. Rather, harvesting
and injection of the conditioned medium from these cells
may be sufficient to harness the potential needed to regen-
erate and repair damaged glomerular filtration membrane.
Future work is needed to define the full potential of this
novel cell-free treatment modality for DN.
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